It Is Time to Overcome the “One-Size-Fits-All” Approach in Chronic Coronary Syndrome?

Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD).1 Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients who underwent elective percutaneous coronary intervention (PCI).1 However, patients with CCS represent a heterogeneous population, and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research